Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Pacts in Medtech

$199.00

Pacts in Medtech – September/October 2016 – notable technology alliances, R&D partnerships and commercial collaborations disclosed in July and August 2016.
November 18, 2016
Find out more
Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

$3,750.00

This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
September 2, 2013
Find out more
Mircera
Read More
Mircera is an ESA administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in CKD
January 11, 2018
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
Fotivda
Read More
Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3. Inhibition of VEGF signaling in order to prevent angiogenesis is a well-established strategy across many tumor types; however, Fotivda’s potency, selectivity, and long half-life are hypothesized to improve the drug’s efficacy and safety in comparison to its predecessors.
March 6, 2019
Find out more
LR769
Read More
LR769 is a recombinant factor VIIa (rfVIIa) therapy in development by LFB for patients with hemophilia A or B with inhibitors.
May 4, 2018
Find out more
FF/UMEC/VI
Read More
FF/UMEC/VI (fluticasone/umeclidinium/vilanterol; GlaxoSmithKline) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (umeclidinium), a long-acting beta 2 agonist (vilanterol), and an inhaled corticosteroid (fluticasone).
April 8, 2016
Find out more
CSL627
Read More
CSL627 is a single-chain rfVIII product in development for hemophilia A. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
March 14, 2016
Find out more
Follicular Lymphoma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.
June 11, 2021
Find out more
bb2121
Read More
Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.
August 9, 2018
Find out more
Triple-Negative Breast Cancer KOL Interview – US

$599.00

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.
October 3, 2019
Find out more
Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain
December 3, 2012
Find out more
Tecentriq
Read More
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.
February 26, 2020
Find out more
GS-5745
Read More
GS-5745 (Gilead) is a humanized monoclonal antibody designed to selectively target the matrix metalloproteinase-9 (MMP9) enzyme. MMP9 plays a key role in the regulation of processes.
July 21, 2016
Find out more
NovoEight
Read More
NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
May 4, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *